Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inter Partes Patent Challenges Are Constitutional, US Supreme Court Rules

Executive Summary

But Patent Trial and Appeals Board must issue final written decision on all claims raised by challenger – not just some of them, court says; rulings in two closely watched cases mean that IPR proceedings can continue unabated, but generic drug and biosimilar sponsors may need to rethink how they go about challenging innovator patent claims.

You may also be interested in...



Patent Day At The Supreme Court: A Split Decision On Split Decisions?

US justices appear divided on whether Patent Trial and Appeal Board can issue a final decision on only some of patent claims challenged. Justice Sotomayor said petitioner is trying to get around the court's Cuozzo decision, but others cited ambiguity in the statute and efficiency of tackling all claims.

Supreme Court Seems Likely To Keep Inter Partes Review Despite Problems

US Justices questioned PTAB panel stacking and ability to challenge patent years after issuance, but the fact decisions can be reviewed by appellate court seemed to allay their concerns.

Will Inter Partes Review Go Away? Supreme Court Weighs Fate

Biopharma and generic industries stand on opposing sides in case that could eliminate the patent challenge proceeding. Interactive timeline covers IPR's five-year history leading to oral arguments Nov. 27.

Related Content

Topics

UsernamePublicRestriction

Register

GB002388

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel